Excellence, Innovation, and Research to Improve Your Quality of Life and Longevity
The number of people dying from liver disease or liver cancer related to chronic viral hepatitis C and B and fatty liver, will increase 2-3 fold by 2020. Of patients with cirrhosis and liver cancer, less than 25% receive routine liver cancer screening. Currently there are over 4,000,000 people with chronic hepatitis C and 2,000,000 people with chronic hepatitis B in the United States who can benefit from treatment. As a result of obesity, there are also about 2,000,000 people with Non-Alcoholic-Steato-Hepatitis (NASH) in the United States. 25% of patients with hepatitis C, hepatitis B or NASH already have cirrhosis. Cirrhosis is the leading cause of liver cancer.
In New Jersey there are over 250,000 people with hepatitis C, hepatitis B or NASH. Unidentified and untreated, the number of people diagnosed with liver cancer may double over the next 10-15 years. By 2025 NASH related cirrhosis will be the leading cause of need for liver transplant in the United States. By that time, there will be at least 2,500,000 people in the United States with cirrhosis. Recent advances in HCV treatment now allow 9 out of 10 patients to successfully be cured of their infection. Treatment of NASH will depend on how we deal with the obesity epidemic.